Last week at the Animal Health, Nutrition, & Technology Innovation Europe conference in London, UK FABP Biotech received The Calan Smith Innovation Award 2025.
This award recognizes FABP Biotech's innovative veterinary vaccine platform technology, which has the potential to revolutionize current treatment processes for parasitic infections in livestock and companion animals. Their platform against helminth parasites uses an engineered, recombinant version of Sm14, a Fatty Acid Binding Protein. A single Drug Substance supports multiple applications, enabling streamlined manufacturing, greater economies of scale, and optimized costs.
FABP Biotech has developed the first vaccines for heartworm disease (Dirofilariasis) in companion animals, and liver fluke (Fasciolosis) in livestock animals. Globally over 800M people are at risk of infection by Helminths, and vaccinating animals against these infections has the potential to minimize spread to humans through food product or environmental contamination.
Darryl Kirsh, Advisor, and Renaud Jacquemart, COO received the award from a panel of expert judges across the field of animal health.
FABP Biotech is currently raising a USD $6-8M Seed Round to fund pivotal clinical studies and product manufacturing, and exploring potential partnerships or out-licensing to animal health pharmaceutical companies. Omnium has partnered with FABP Biotech for fundraising efforts, and interested investors and animal health companies should reach out to us to learn more about this opportunity.
Congratulations FABP Biotech! We are proud to be a part of your success.
